期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 13, 期 8, 页码 1774-1777出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2017.1321725
关键词
adjuvant; cancer immunotherapy; cancer vaccine; Toll-like receptors
资金
- European Union's 7th Framework Programme for Research, Project Cancer Vaccine development for Hepatocellular Carcinoma - HEPAVAC [602893]
- Italian Ministry of Health through Institutional Ricerca Corrente
Cancer vaccines are designed to stimulate the body's immune system to kill tumor cells. To improve their immunogenicity, vaccine antigens must be combined with adjuvants which are able to stimulate the innate immunity and potentiate the adaptive immune response. In the last years a new generation of adjuvants mimicking the natural microbial ligands have been developed. In particular, several TLR ligands have been extensively explored as vaccine adjuvants and many preclinical and clinical studies have been conducted. However, the road to approval of such adjuvants for clinical use is still to go.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据